CMYC和PD-L1表达与DLBCL临床病理特征及预后的关系分析  

Analysis of the Relationship Between the Expression of CMYC and PD-L1 and Clinical Characteristics and Prognosis of DLBCL Patients

作　　者：黄金 杨如玉[1] 华银玲[1] HUANG Jin;YANG Ruyu;HUA Yinling(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2022年第9期1433-1435,共3页The Practical Journal of Cancer

摘　　要：目的探讨CMYC和PD-L1表达与弥漫大B细胞淋巴瘤(DLBCL)临床病理特征及预后的关系。方法选取DLBCL患者92例,免疫组化法检测CMYC及PD-L1蛋白的表达,分析其与DLBCL临床病理特征的关系。结果92例DLBCL组织中72例CMYC蛋白为阳性,阳性率为78.3%,76例PD-L1蛋白为阳性,阳性率为82.6%;Ann Arbor分期Ⅲ~Ⅳ期、有骨髓侵犯的DLBCL患者CMYC及PD-L1的表达阳性率显著高于Ann Arbor分期Ⅰ~Ⅱ期及无骨髓侵犯者(P均<0.05);预后不良组中CMYC及PD-L1的表达阳性率显著高于预后良好组,且Ann Arbor分期为Ⅲ~Ⅳ的患者占比显著高于预后良好组(P<0.05);Logistic回归分析发现,CMYC阳性、PD-L1阳性及Ann Arbor分期均是DLBCL预后不良的独立危险因素(P<0.05)。结论CMYC及PD-L1蛋白在DLBCL患者中特异性高表达,且是DLBCL患者预后判断的潜在指标,值得临床推广应用。Objective To investigate the relationship between the expression of CMYC and PD-L1 andand clinical characteristics and prognosis of DLBCL patients.Methods The expression of CMYC and PD-L1 protein was detected by immunohistochemistry in 92 cases of DLBCL patients,and their relationship with the clinicopathological characteristics of DLBCL was analyzed.Results Among 92 DLBCL tissues,72 were positive for CMYC protein,with a positive rate of 78.3%,and 76 were positive for PD-L1 protein,with a positive rate of 82.6%;The positive rates of CMYC and PD-L1 expression in DLBCL patients with Ann Arbor stageⅢ~Ⅳand bone marrow invasion were significantly higher than those with Ann Arbor stageⅠ~Ⅱand without bone marrow invasion(P<0.05).The percentage of patients with Ann Arbor stageⅢ~Ⅳwas significantly higher than that of patients with good prognosis(P<0.05);Logistic regression analysis revealed that CMYC positivity,PD-L1 positivity and Ann Arbor stage were independent risk factors for poor prognosis of DLBCL(P<0.05).Conclusion CMYC and PD-L1 proteins are specifically and highly expressed in DLBCL patients and are potential indicators for prognosis of DLBCL patients,which are worthy of clinical application.

关 键 词：弥漫大B细胞淋巴瘤 细胞性骨髓细胞瘤病病毒癌基因 细胞程式死亡-配体1临床特征 预后 

分 类 号：R733.4[医药卫生—肿瘤]